Semaglutide vs Tirzepatide: research-use prices, identity and FDA status (2026)
Semaglutide and Tirzepatide are different research compounds, not substitutes for each other: Semaglutide is a single compound (C187H291N45O59); Tirzepatide is a single compound (C225H348N48O68). Neither product has a current in-stock price right now. Semaglutide shares its active ingredient with an FDA-approved prescription medicine; Tirzepatide shares its active ingredient with an FDA-approved prescription medicine.
Research use only. These are research-use-only listings sold for laboratory research, not prescription medicines and not for human use. PeptideTech does not compare effects or provide dosing information.
Semaglutide vs Tirzepatide: current prices and packages
| Compared property | Semaglutide | Tirzepatide |
|---|---|---|
| Category | GLP-1 | GLP-1 |
| Compared package | 10mg | 30mg |
| Lowest current price | No current in-stock price | No current in-stock price |
| Price per labelled mg | — | — |
| Package sizes | 5mg, 10mg, 15mg, 20mg, 30mg, 50mg | 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 100mg |
| Vendors with current prices | 0 | 0 |
| Form at this package | No listing | No listing |
| Stock | Out of stock | Out of stock |
Prices exclude shipping. The price per labelled mg is always given per mg, so different package sizes compare directly; it is shown only for single-compound vials and powders with a labelled mass. Blends, capsules, liquids and IU-labelled packages are compared by package total.
Identity, regulatory status and registered research
| Compared property | Semaglutide | Tirzepatide |
|---|---|---|
| Molecular formula | C187H291N45O59 | C225H348N48O68 |
| Molecular weight | 4114 g/mol | 4813 g/mol |
| Sequence | — | — |
| CAS Registry Number | 910463-68-2 | — |
| Registered clinical trials | 34 (34 active) · Phase 4: 8, Phase 3: 12, Phase 2: 2 | 38 (38 active) · Phase 4: 9, Phase 3: 6, Phase 2: 14 |
| Human intervention studies | 5 | 7 |
| US regulatory status | FDA-approved prescription medicine with this active ingredient: Ozempic, Rybelsus and Wegovy (NDA 209637, NDA 213051, NDA 213182, NDA 215256 and NDA 218316; checked October 7, 2026)MarketedOZEMPIC · NDA 209637 · 2017OZEMPIC / RYBELSUS · NDA 213051 · 2019RYBELSUS · NDA 213182 · 2020WEGOVY · NDA 215256 · 2021WEGOVY · NDA 218316 · 2025Research listings are not these medicines. | FDA-approved prescription medicine with this active ingredient: Mounjaro and Zepbound (NDA 215866 and NDA 217806; checked October 7, 2026)MarketedMOUNJARO · NDA 215866 · 2022ZEPBOUND · NDA 217806 · 2023Research listings are not these medicines. |
Identity data: PubChem, FDA GSRS and EPA records; registry counts: ClinicalTrials.gov; status: Drugs@FDA. A matching name does not verify the contents of a supplier's lot.
Key human studies
Semaglutide
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2025
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism, 2022
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2021
Tirzepatide
- Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England journal of medicine, 2025
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine, 2025
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England journal of medicine, 2024
Studies are listed as records, newest first; they are not evidence that a research product is safe or effective.
Research-use listings for each compound
Research-use-only listings sold for laboratory research, not prescription medicines and not for human use.
Semaglutide
Semaglutide is a GLP-1 receptor agonist and the active substance in the EU-authorized prescription medicine Wegovy. Evidence and authorization attach to specified medicinal products and their studied use.
No vendor has a current in-stock price for this package.
Semaglutide prices →Price history →Tirzepatide
Tirzepatide acts at GIP and GLP-1 receptors and is the active substance in the EU-authorized prescription medicine Mounjaro. Its medicinal-product assessment is separate from a supplier’s research catalogue listing.
No vendor has a current in-stock price for this package.
Tirzepatide prices →Price history →Related comparisons
Questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. A code is shown when it is attached to an offer or affiliate link. The displayed price includes a discount only when that code is cart-verified and the discounted price is explicitly recorded; otherwise it is the vendor's listed price. Prices exclude shipping. Stock status is captured at the same time. Rankings are by displayed price, except that the labelled featured partner, LA Peptides, is pinned first; “Cheapest” always marks the lowest price. PeptideTech earns a commission when you buy through a link.
Full method →